Investigation abut the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 03 Mar 2017 New trial record